<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144556">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01836185</url>
  </required_header>
  <id_info>
    <org_study_id>14621</org_study_id>
    <secondary_id>I1V-MC-EIAS</secondary_id>
    <nct_id>NCT01836185</nct_id>
  </id_info>
  <brief_title>A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment</brief_title>
  <official_title>Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how much of the drug gets into the bloodstream and
      how long it takes the body to remove it when given to participants with hepatic (liver)
      impairment compared to participants with normal hepatic function. Information about any side
      effects that may occur will also be collected.  This study will last approximately 28 days,
      not including screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During One Dosing Interval (AUC[0-Ï„]) of Evacetrapib</measure>
    <time_frame>Pre-dose up to 14 days post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib</measure>
    <time_frame>Pre-dose up to 14 days post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib</measure>
    <time_frame>Pre-dose up to 14 days post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Evacetrapib (Healthy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: 130 mg evacetrapib administered once, orally, to participants with normal hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib (Hepatic, Mild)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib (Hepatic, Moderate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib (Hepatic, Severe)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <arm_group_label>Evacetrapib (Healthy)</arm_group_label>
    <arm_group_label>Evacetrapib (Hepatic, Mild)</arm_group_label>
    <arm_group_label>Evacetrapib (Hepatic, Moderate)</arm_group_label>
    <arm_group_label>Evacetrapib (Hepatic, Severe)</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants have given written informed consent approved by the ethical review board
             (ERB) governing the site

          -  Female participants should be of non-childbearing potential

          -  Have a body mass index of 18 to 40 kilograms per square meter (kg/m^2)

          -  Healthy participants have normal hepatic function as determined by medical history,
             physical examination, and other screening procedures

          -  Individuals with hepatic impairment classified as Child-Pugh score A, B, or C (mild,
             moderate, or severe impairment)

        Exclusion Criteria:

          -  Has had esophagus variceal bleeding within 3 months of check-in

          -  Have the need to take medications that may interfere with how the liver removes the
             drug

          -  Have evidence of cancer in the liver

          -  Consumes excessively large amounts of drinks with caffeine or alcohol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
